LEO Pharma Inc. Announces New Vice President of Sales

Jul 06, 2015, 10:47 ET from LEO Pharma Inc.

PARSIPPANY, N.J., July 6, 2015 /PRNewswire/ -- Today, LEO Pharma Inc. announced that Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales.  "Mitch is a welcomed addition to our team.  He is an energetic sales leader and strategist with proven results in the pharmaceutical industry," stated Barbara Osborne, President & CEO, LEO U.S.  Johnson stated, "I am proud to be joining LEO Pharma and look forward to supporting our mission of helping people achieve healthy skin." 

Johnson has over 25 years of experience in the pharmaceutical industry with an emphasis in sales management.  Prior to joining LEO, Johnson held the position of Vice President, Sales – Respiratory at GlaxoSmithKline.   While at GlaxoSmithKline, Johnson also held positions as Executive Director of the Influenza Franchise, Regional Sales Vice President of General Pharma, and Product Manager in the Diabetes Franchise.  Prior to entering the pharmaceutical industry, Johnson played professional baseball for 10 years. 

Johnson holds a Bachelor of Science in Business Administration from Bryant University in Rhode Island, and a Master of Business Administration from Duke University in Durham, North Carolina. 

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide.

Media Contact:

Nora Masin, Specialist, Communications
LEO Pharma Inc.
nora.masin@leo-pharma.com
(973)637-1611

Regina Donohue, VP, Human Resources
LEO Pharma Inc.
regina.donohue@leo-pharma.com
(973)637-1690

Photo - http://photos.prnewswire.com/prnh/20150706/230671

SOURCE LEO Pharma Inc.